Safety and tolerability of treatments for allergic rhinitis in children

Drug Safety

Volumn 27, Issue 12, 2004, Pages 883-898

  Baena Cagnani, Carlos E ^a  

^a UNIVERSIDAD CATÓLICA DE CÓRDOBA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; ASTEMIZOLE; BECLOMETASONE; BUDESONIDE; CETIRIZINE; CHROMONE DERIVATIVE; CORTICOSTEROID; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; DESLORATADINE; DIPHENHYDRAMINE; EBASTINE; ERYTHROMYCIN; FEXOFENADINE; FLUNISOLIDE; FLUTICASONE PROPIONATE; HISTAMINE H1 RECEPTOR; KETOCONAZOLE; LEVOCETIRIZINE; LORATADINE; LYPRESSIN; MIZOLASTINE; MOMETASONE FUROATE; TECASTEMIZOLE; TERFENADINE; TRIAMCINOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ADRENAL CORTEX INSUFFICIENCY; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; BONE METABOLISM; BURNING SENSATION; CARDIOTOXICITY; CHILD; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRY NOSE; EVIDENCE BASED MEDICINE; FIRST PASS EFFECT; GROWTH DISORDER; HEADACHE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOTHERAPY; LEARNING DISORDER; LIPOPHILICITY; METABOLIC DISORDER; NOSE CONGESTION; NOSE IRRITATION; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROVOCATION TEST; PSYCHOMOTOR DISORDER; QT PROLONGATION; REBOUND; REVIEW; RHINITIS; RHINITIS MEDICAMENTOSA; SEDATION; SIDE EFFECT; SYMPTOM; TACHYCARDIA; TACHYPHYLAXIS; URINE RETENTION; XEROSTOMIA;

ADMINISTRATION, INTRANASAL; ADRENAL CORTEX HORMONES; ADULT; CHILD; CLINICAL TRIALS; DOUBLE-BLIND METHOD; HISTAMINE H1 ANTAGONISTS; HUMANS; RHINITIS, ALLERGIC, PERENNIAL;

EID: 4944242686     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200427120-00005     Document Type: Review

References (86)

1. ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema. Lancet 1998; 351: 1225-32
2. Bousquet J, Van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001 Nov; 108 (5 Suppl.): S147-334
3. Wright AL, Holberg CJ, Martinez FD, et al. Epidemiology of physician diagnosed allergic rhinitis in childhood. Pediatrics 1994; 94: 895-901
4. Galant SP, Wilkinson R. Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child. Biodrugs 2001; 15: 453-63
5. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998; 81: 478-518
6. Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001; 108 Suppl. 1: S45-53
7. Settipane RA. Complications of allergic rhinitis. Allergy Asthma Proc 1999; 20: 209-13
8. Baena-Cagnani C. Allergic rhinitis and asthma in children: disease management and outcomes. Curr Allergy Asthma Rep 2001; 1: 515-22
9. van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. Allergy 2000; 55: 116-34
10. Jumbelic MI, Hanzlick R, Cohle S. Alkylamine antihistamine toxicity and review of pediatric registry of the National Association of Medical Examiners. Am J Forensic Med Pathol 1997; 18: 65-9
11. Garza MB, Osterhoudt KC, Rutstein R. Central anticholinergic syndrome from orphenadrine in a 3-year-old. Pediatr Emerg Care 2000; 16: 97-6
12. Goetz CM, Lopez G, Dean BS, et al. Accidental childhood death from diphenhydramine overdosage. Am J Emerg Med 1990; 8: 321-2
13. Le Blaye I, Donatini B, Hall M, et al. Acute ketotifen overdosage: a review of present clinical experience. Drug Saf 1992; 7 (5): 387-92
14. Hindmarch I, Shamsi Z. Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy 1999; 29 Suppl. 3: 133-42
15. Baena-Cagnani CE. Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy 2001; 65 Suppl. 56: 21-7
16. Brannan JD, Anderson SD, Gomes K, et al. Fexofenadine decreases sensitivity to and montelukast improves recovery from inhaled mannitol. Am J Respir Crit Care Med 2001; 163: 1420-5
17. The ETAC Group. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomized, placebo-controlled trial: first results of ETAC Early Treatment of the Atopic Child. Pediatr Allergy Immunol 1998; 9 (3): 116-24
18. Graft DF, Bernstein DI, Goldsobel A, et al. Safety of fexofenadine in children treated for seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001; 87: 22-6
19. Wahn U, Hedlin G, Ruuth E, et al. Assessment of safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis [abstract]. Allergy 2002; 57 Suppl. 73: 673
20. Tinkelman DJ, Kemp J, Mitchell DQ, et al. Treatment of seasonal allergic rhinitis in children with cetirizine and chlorpheniramine: a multi-center study. Pediatr Asthma Allergy Immunol 1996; 10: 9-17
21. Baelde Y, Dupont P. Cetirizine in children with chronic allergic rhinitis. Drug Invest 1992; 4: 466-72
22. Allegra L, Paupe J, Wieseman HG, et al. Cetirizine for seasonal allergic rhinitis in children aged 2-6 years: a double-blind comparison with placebo. Pediatr Allergy Immunol 1993; 4 (3): 157-61
23. Simons FER. Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC Study Group: early treatment of the atopic child. J Allergy Clin Immunol 1999; 104: 433-40
24. Lutsky BN, Klose P, Melon M, et al. A comparative study of the efficacy and safety of loratadine and terfenadine suspension in the treatment of 3 to 6 year old children with SAR. Clin Ther 1993; 15: 855-65
25. Delgado LF, Pferferman A, Sole D, et al. Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine and cetirizine in atopic children. Ann Allergy Asthma Immunol 1998; 80: 333-7
26. Ellis J, Seidenberg M. Desloratadine is a potent antagonist at muscarinic acetylcholine receptors, but fexofenadine, is not [abstract]. Allergy 2001; 56 Suppl. 68: 202, 642
27. Igawa A, Cheg CP, Little W. Desloratadine, but no fexofenadine, increases the heart rate in dogs before and after heart failure. Allergy 2001; 56 Suppl. 68: 203-4
28. Tobin JR, Doyle TP, Ackerman AD, et al. Astemizole-induced cardiac conduction disturbances in a child. JAMA 1991; 266: 2737-40
29. Hoppu K, Tikanoja T, Tapanainen P, et al. Accidental astemizole overdose in young children. Lancet 1991; 338: 538-40
30. Wiley II JF, Gelber ML, Henretig FM, et al. Cardiotoxic effects of astemizole overdose in children. J Pediatr 1992; 120: 799-802
31. Simons FER, Kesselman MS, Giddens NG, et al. Astemizole-induced torsade de pointes [letter]. Lancet 1988; 11: 624
32. Pratt C, Brown A, Rampe D, et al. Cardiovascular safety of fexofenadine HCl. Clin Exp Allergy 1999; 29 (3): 212-6
33. Taglialatela M, Castaldo P, Pannaccione A, et al. Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. Clin Exp Allergy 1999; 29 Suppl. 3: 182-9
34. Zhou A, Vorperian VR, Gong Q, et al. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol 1999; 10: 836-43
35. Crumb WJ. Loratadine blockade of K+ channels in human heart: comparison with terfenadine under physiological conditions. J Pharmacol Exp Ther 2000; 292: 261-4
36. Winder J, Noonan MJ. A randomized, placebo-controlled study to evaluate the cardiographic effects of cetirizine in children aged 6 to 11 [abstract]. J Allergy Clin Immunol 1996; 97: 342
37. Harrison JE, Danzig MR, Lorber RR. The electrocardiographic effects of loratadine syrup in pediatric patients [abstract]. J Allergy Clin Immunol 1996; 97: 437
38. Simons FER. H1-antihistamines in children. In: Simons FER, editor. Histamine and H1-antihistamines in allergic disease. 2nd ed. New York: Marcel Dekker Inc, 2002: 437-64
39. Passalacqua G, Scordamaglia A, Ruffoni S, et al. Sedation from H1 antagonists: evaluation methods and experimental results. Allergol Immunopathol (Madr) 1993; 21: 79-83
40. Cookson J, Taylor D, Katona C. Use of drugs in psychiatry. 5th ed. London: Gaskell, 2002: 408
41. Yasahara A, Ochi A, Harada Y, et al. Infantile spasms associated with a histamine H1-antagonist. Neuropediatrics 1998; 29: 320-1
42. Yokoyama H, Iinuma K, Yanai K, et al. Proconvulsant effect of ketotifen, a histamine H1-antagonist, confirmed by the use of d-chloropheniramine with monitoring electroencephalography. Methods Find Exp Clin Pharmacol 1993; 15: 183-8
43. Vuurman E, van Veggel L, Uiterwijk M, et al. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 1993; 71: 121-6
44. Simons FE. Learning impairment and allergic rhinitis. Allergy Asthma Proc 1996 Jul-Aug; 17 (4): 185-9
45. Falliers CJ, Brandon ML, Buchman E, et al. Double-blind comparison of cetirizine and placebo in the treatment of seasonal rhinitis. Ann Allergy 1991 Mar; 66 (3): 257-62
46. Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy 2002; 32: 133-9
47. Ridout F, Meadows R, Johnsen S, et al. Effects of desloratadine 5, 10 and 20mg, and promethazine 25mg on cognitive and psychomotor performance [abstract]. Ann Allergy Asthma Immunol 2003; 90 (1): 124, P35
48. Feldman W, Shanon A, Leiken L, et al. Central nervous system side-effects of antihistamines in schoolchildren. Rhinology 1992; 13: 13-9
49. Simons FER, Reggin JD, Roberts JR, et al. Benefit/risk ratio of the antihistamines (h1-receptor antagonists) terfenadine and chlorpheniramime in children. J Pediatr 1994; 124: 979-83
50. Simons FER, Fraser TG, Reggin JD, et al. Adverse central nervous system effects of older antihistamines in children. Pediatr Allergy Immunol 1996; 7: 22-7
51. Stevenson J, Cornah D, Evrard P, et al. and The ETAC Study Group. Long-term evaluation of the impact of the H1-receptor antagonist cetirizine on the behaviour, cognitive and psychomotor development of very young children with atopic dermatitis. Pediatr Res 2002; 52 (2): 251-7
52. Allen DB. Systemic effects of intranasal steroids: an endocrinologist's perspective. J Allergy Clin Immunol 2000; 106: S179-90
53. Sizonenko PC. Effects of inhaled or nasal glucocorticosteroids on adrenal function and growth. J Pediatr Endocrinol Metab 2002; 15: 5-26
54. Kokron CM, Castro AS, Sole D, et al. Lysine-vasopressin in the evaluation of the hypothalamic-pituitary-adrenal axis in children with allergic rhinitis treated with intranasal beclomethasone dipropionate or oral prednisone. J Investig Allergol Clin Immunol 1997; 7: 51-6
55. Grossman J, Banov C, Bronsky EA, et al. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Pediatrics 1993; 92: 594-9
56. Agertoft L, Wolthers OD, Fuglsang G, et al. Nasal powder administration of budesonide for seasonal rhinitis in children and adolescents. Pediatr Allergy Immunol 1993; 4: 152-6
57. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray [abstract]. Pediatrics 2000; 105: E22
58. Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate [abstract]. Pediatrics 2000; 105: E23
59. Treatment of seasonal allergic rhinitis with once-daily intranasal fluticasone propionate therapy in children: Fluticasone Propionate Collaborative Pediatric Working Group. J Pediatr 1994; 125: 628-34
60. Skoner D, Gentile D, Angelini B, et al. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol 2003; 90: 56-62
61. Brannan MD, Herron JM, Affrime MB, et al. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther 1997; 19: 1330-9
62. Meltzer EO, Berger WE, Berkowitz RB, et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 107-14
63. Nayak AS, Ellis MH, Gross GN, et al. The effects of triamcinolone acetonide aqueous nasal spray on adrenocorticol function in children with allergic rhinitis. J Allergy Clin Immunol 1998; 101: 157-62
64. Wolthers OD, Pedersen S. Short-term growth in children with allergic rhinitis treated with oral antihistamine, depot and intranasal glucocorticosteroids. Acta Paediatr 1993; 82: 635-40
65. Wolthers OD, Pedersen S. Knemometric assessment of systemic activity of once daily intranasal dry-powder budesonide in children. Allergy 1994; 49: 96-9
66. Agertoft L, Pedersen S. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J Allergy Clin Immunol 1999; 104 (5): 948-52
67. Mansfield LE, Mendoza CP. Medium and long-term growth in children receiving intranasal beclomethasone dipropionate: a clinical experience. South Med J 2002; 95: 334-40
68. Allen DB, Meltzer EO, Lemanske Jr RF, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 2002; 23: 407-13
69. Wilson A, Sims EJ, McFarlane LC, et al. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol 1998 Oct; 102: 598-604
70. Martinati LC, Sette L, Chiocca E, et al. Effect of beclomethasone dipropionate nasal aerosol on serum markers of bone metabolism in children with seasonal allergic rhinitis. Clin Exp Allergy 1993; 23: 986-91
71. Toogood JH, Jennings B, Crepea SB, et al. Efficacy and safety of concurrent use of intranasal fluinsolide and oral beclomethasone aerosols in the treatment of asthmatics with rhinitis. Clin Allergy 1982; 12: 95-105
72. Herman D, Garay R, Le Gal M, et al. A randomized, double-blind, placebo controlled study of azelastine nasal spray in children with perennial allergic rhinitis. Int J Pediatr Otorhinolaryngol 1997; 39: 1-8
73. Azelastine (Astelin®) prescribing information [online]. Available from URL: http://www.astelin.com/productinfo/pi.html#adverse1 [Accessed 2003 Jan]
74. Schenkel EJ. Paediatric issues relating to the pharmacotherapy of allergic rhinitis. Expert Opin Pharmacother 2000; 1: 1289-306
75. Bousquet J, Lockey RF, Malling H-J. WHO position paper: allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998; 53 Suppl. 44: 1-42
76. Passalacqua G, Canonica GW. Alternative routes of immunotherapy: a review. J Invest Allergol Clin Immunol 1996; 36: 81-7
77. Purello-D'Ambrosio F, Gangemi S, Merendino RA, et al. Prevention of new sensitizations in mono sensitized subjects submitted to specific immunotherapy or not: a retrospective study. Clin Exp Allergy 2001; 31: 1295-302
78. Pajno G, Barberio G, De Luca F, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy: a six-year follow-up study. Clin Exp Allergy 2001; 31: 1392-7
79. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109: 251-6
80. Philip G, Malmstrom K, Hampel FC, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002; 32: 1020-8
81. Wilson AM, Sims EJ, Orr LC, et al. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001; 87: 344-9
82. Pullerits T, Praks L, Ristioja V, et al. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109: 949-55
83. Wilson AM, Orr LC, Coutie WJ, et al. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhintis. Clin Exp Allergy 2002; 32: 126-32
84. Casale TB. Experience with monoclonal antibodies in allergic mediated disease: seasonal allergic rhinitis. J Allergy Clin Immunol 2001 Aug; 108 (2 Suppl.): S84-8
85. Naclerio R, Rosenwasser L, Ohkubo K. Allergic rhinitis: current and future treatments. Clin Exp Allergy Rev 2002; 2: 137-47
86. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999 May 10; 159 (9): 941-55